At ThinkGenetic, Inc. our goal is to reduce the time to diagnosis for genetic and rare conditions. Given they are rare, we must be cognizant of the time it takes […]
Guardian Research Network, Inc.® (GRN) and ThinkGenetic, Inc. announce a strategic collaboration to accelerate the diagnosis and support the development of treatment options for patients with rare and genetic diseases.
Horizon Therapeutics plc (Nasdaq: HZNP), in collaboration with MIT Solve, a marketplace for social impact innovation, is proud to announce two winning solutions of this year’s Horizon Prize, ThinkGenetic Inc. and Congenica.
ThinkGenetic, Inc. announces the official acceptance of a $500,000 investment from the Ochsner Lafayette General Healthcare Innovation Fund.
Most medical treatments fall into four broad categories based on their goal: For the most part, treatments for genetic diseases have fallen into the preventive, disease management, or palliative categories. […]